MANAGEMENT & CONSULTANTS

Rhonda F. Rhyne, M.B.A.

President & CEO

Rhonda Rhyne has spent the past 20 years in executive management for biotechnology and medical technology companies.  She has served as Chief Executive Officer and Board Director for Prevencio since August 2013. Previously, she served as Chief Operating Officer and then President of CardioDynamics, a publicly traded, innovative cardiovascular medical device company from 1996 to 2009.  The company was sold to Sonosite, Inc. (now Fujifilm Holdings Corp., OTCPK: FUJIY) in August 2009.

 

Ms. Rhyne served as Chief Executive Officer and Board Director for Culture Technology, Inc., a privately-held biotechnology company specializing in growing skin for severely burned patients from 1992 to 1995. 

 

Ms. Rhyne also founded Rhyne Life Sciences Consulting, a consultancy practice focused on emerging life science technologies. 

 

She has received numerous awards including Ernst & Young’s Entrepreneur of the Year for Medical Products; Deloitte’s Technology Fast 50 award for the 50 fastest-growing technology and life science companies in Southern California for successive nine years; San Diego Business Journal’s Women Who Mean Business award; and Athena’s Pinnacle award for supporting women in bioscience business.

 

Ms. Rhyne has an MBA from The Anderson School of Management at University of California at Los Angeles (UCLA) and a Bachelor of Pharmacy from Washington State University.

Dean Loizou, B.S.

Vice President of Business Development

Dean Loizou is the Vice President of Business Development for Prevencio.   Previously, he served for 26 years with Abbott Diagnostics in roles including Business Development, Strategic Planning, Marketing, R&D, Sales, Engineering, and Change Management.   

 

During his tenure at Abbott, Mr. Loizou served in business development leadership roles including integrations and divestitures as well as global alliance management of partners inclusive of product development, manufacturing, licensing & distribution agreements.  His accomplishments also included global product launches in Transfusion, Molecular, Clinical Chemistry, Hematology, and Laboratory Automation.  

 

Mr. Loizou has a Bachelor’s of Science in Engineering from Northwestern University.

Grady Barnes, Ph.D.

Chief Scientific Officer

Grady Barnes, PhD, serves as Chief Scientific Officer and has a 20+ year history as a Research & Development executive with leadership experience as a Product Developer, Director, VP, and Chief Scientific Officer.  Prior to joining the company, Grady held various positions at Abbott, Meridian Biosciences, Fujirebio Diagnostics, and Leica Biosystems.

 

Dr. Barnes has launched more than 100 in vitro diagnostic (IVD) products, including diagnostic assay kits, hardware, and software. He has rich knowledge of the entire product life cycle from concept to post-market surveillance and has been involved in National and International product launches including Europe, Canada, Japan, and China.

Dr. Barnes received his Bachelor of Arts in Natural Sciences/Biology from The John Hopkins University in Baltimore, Maryland, and his Ph.D. in Biochemistry from Florida State University at Tallahassee, Florida.

Celine Peters, R.N., M.N.

Vice-President of Clinical Development

 

Celine Peters is Vice-President of Clinical Development for Prevencio. Prior to joining Prevencio, Ms. Peters held positions within healthcare as a Cardiovascular Clinical Nurse Specialist, Quality Management Director, Patient Safety Officer, and Clinical Research & Outcomes Management Director. She has also held clinical marketing positions for pharmaceutical and medical device companies including CardioDynamics/Sonosite, and Crisi Medical/Becton Dickinson. 

 

Ms. Peters' industry positions included development of strategy and research plans; Human Factors research; educational strategies to support product development and sales; publications; and regulatory approval of medical devices.

 

Ms. Peters received her Master’s in Nursing from the University of California, Los Angeles.

Craig A. Magaret, M.S.

Chief Analytics Officer

 

Craig Magaret has extensive experience with data analysis and management in a regulated clinical environment, as well as bioinformatics and high-dimensional data mining.

His work history includes more than fifteen years with the Fred Hutchinson Cancer Research Center (FHCRC), where he focused on the analysis of data from genomic sequences, expression arrays, and various proteomic and immunological assays.  As the Associate Director of the Computational Biology Core of the FHCRC's Vaccine and Infectious Disease Division, Mr. Magaret led and performed bioinformatic and analytical efforts with various data-driven discovery and analysis projects.  His work has contributed to the efforts of several international NIH-funded clinical research networks, as well as the Coalition for AIDS Vaccine Discovery funded by the Bill and Melinda Gates Foundation. 

Mr. Magaret was also the Bioinformatics Manager with Immunexpress, Inc., where he managed the day-to-day bioinformatics, data management, and analytics efforts with gene expression and proteomic biomarker discovery, and the development of diagnostic and monitoring algorithms.  Additionally, Mr. Magaret has served as an analytical consultant for various firms in the capacity of biomedical research and data mining, assisting small clients with high-dimensional data analysis, typically in the field of biomarker discovery and molecular diagnostics.  Among his work in this area was a two-year collaboration with the Naval Medical Research Center, doing proteomic biomarker discovery in the domain of combat medicine.

Mr. Magaret has a Master's Degree in Computer Science and Engineering from the University of Washington, where he specialized in computational biology and data mining, as well as Bachelor's degrees in Statistics, Zoology and Anthropology, also from the University of Washington.  Between his sessions in undergraduate and graduate school, Mr. Magaret completed a post-baccalaureate research fellowship with Stanford University in mathematical biology.

Vipul Shah, M.B.A., C.P.A.

Vice President, Finance

 

Mr. Shah has an extensive financial and accounting background, spanning 30 years, and has held senior management positions with a wide range of companies, including biotechnology and technology start-ups, larger financial institutions, and venture capital entities.  During his career, he has overseen a variety of functions including financial reporting, financial planning and analysis, general tax and accounting, business modeling and valuations, and strategic planning.  

 

Prior to his current position, Mr. Shah was VP and CFO of the Wholesale Mortgage Division at Washington Mutual. In this position, Mr. Shah was responsible for all financial analysis and reporting to the Wholesale team that was responsible for $50 billion in production. Prior to Washington Mutual, Mr. Shah held several senior finance positions, including VP of Finance for Ondine and VP of Incepta Ventures. Most notably. Mr. Shah was part of the team that took Ondine public in Canada.  At Incepta, his primary roles were valuations of business opportunities and auction strategy for wireless license auctions.  Mr. Shah has an MBA and Masters of Professional Accounting from the University of Washington.  

James L. Januzzi, M.D., F.A.C.C., F.E.S.C.

Principal Investigator

 

Dr. Januzzi is the company’s Principal Investigator for the Casablanca trial, a practicing cardiologist at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School.  He has extensive experience with cardiac biomarker testing, including troponins, inflammatory markers, novel tests such as ST2, galectin-3, GDF-15, and the natriuretic peptides.

Dr. Januzzi serves as Chairman of the International NT-proBNP Consensus Panel and the International ST2 Consensus Panel; section editor for the ACC/AHA Guidelines for the Diagnosis and Management of Heart Failure; and lead author of the heart failure section for the Universal Definition of Myocardial Infarction Global Task force.

He is widely published with more than 400 peer-reviewed manuscripts, reviews and chapters, as well as three textbooks. Dr. Januzzi is an active and experienced cardiology clinician, with a large clinical practice focused on heart failure and coronary artery disease. He has also served as cardiovascular disease consultant to the Boston Red Sox baseball club since 2005.

William A. LaFramboise, Ph.D.

Co-Founder, Consultant, Chief Genomics Technology Officer, Allegheny Health Network

 

Dr. William (Bill) LaFramboise is a Prevencio co-founder who has an active and diverse research program spanning numerous departments and institutions at the Allegheny Health Network. Currently, he is Chief Genomics Technology Officer, Allegheny Health Network and Allegheny Cancer Institute.   One of Dr. LaFramboise research interests is the study of clinically important cardiac proteins.

 

Previously, Dr. LaFramboise was the Director of Clinical Sequencing Facility/Cancer Biomarkers Facility at the University of Pittsburgh Medical Center (UPMC).  Dr. LaFramboise also collaborated with the UPMC Department of Cardiology. 

 

Dr. LaFramboise has held positions including: Associate Professor and Director of the Applied Molecular Research Microarray Facility, Department of Cardiothoracic Surgery, at the Allegheny General Hospital in Pittsburgh, PA; Director of Laboratory Development & Operations at TissueInformatics, Inc., in Pittsburgh; and Director of Cellular & Molecular Myology Laboratory in the Department of Pediatrics at Drexel University Medical School.

 

He has a Ph.D. in Molecular Neurobiology from the University of Pittsburgh and a B.A. in Philosophy from the University of Washington.